Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Increased CD8+ T Cell Response to Epstein-Barr Virus Lytic Antigens in the Active Phase of Multiple Sclerosis.
Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients.
Prevention and treatment of MS: studying the effects of vitamin D.
Food and Drug Administration Approval Letter for Alemtuzumab
Effects of murine and human bone marrow-derived mesenchymal stem cells on cuprizone induced demyelination.
MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial
The history of the oxazaphosphorine cytostatics.
Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study.
Peripheral and Central Nervous System Drugs Advisory Committee Meeting: Alemtuzumab (BLA 103948\5139) Background Package
A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis.
Multigate Quality Doppler Profiles and Morphological/Hemodynamic Alterations in Multiple Sclerosis Patients.
Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome.
Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis.
Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group.
Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
Comparing the biological impact of glatiramer acetate with the biological impact of a generic.
Transverse myelitis -- a review of the presentation, diagnosis, and initial management.
Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis.
Guillain-Barré syndrome: clinical profile and management.
Stress Management and Multiple Sclerosis: A Randomized Controlled Trial.
Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1.
Teva Announces U.S. Supreme Court Will Hear Its Appeal on COPAXONE(R) Patent
Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship.
Receptos, Inc. - Current Report: United States Securities and Exchange Commission Form 8-K
Yield of emergent neuroimaging among children presenting with a first complex febrile seizure.

Pages